VN January 2021
Vetnuus | Januarie 2021 38 In this study Marina Rodríguez and colleagues in Dubai evaluated the immune response of horses to inactivated African horse sickness (AHS) vaccines. A total of 29 horses in two groups were vaccinated. Group 1 consisted of 18 horses which were further divided into nine subgroups of two horses. These horses were individually immunised with one of 1 to 9 AHS serotypes. Group 2 consisted of 11 horses that were immunised with all nine serotypes simultaneously with two different vaccinations, one containing serotypes 1, 4, 7, 8 and 9, and the other containing serotypes 2, 3, 5 and 6. The duration of this study was 12 months. Blood samples were periodically withdrawn for serum antibody tests using ELISA and VNT and for 2 weeks after each vaccination for PCR and virus isolation. After the booster vaccination, 27 horses seroconverted; however, two horses responded poorly as measured by ELISA. In Group 1 ELISA andVN antibodies declined between 5–7 months post‐vaccination. After 12 months the antibody levels in most of the horses decreased to the seronegative range until the annual booster where all horses again seroconverted strongly. In Group 2, ELISA antibodies were positive after the first booster and VN antibodies started to appear for some serotypes after primary vaccination. After booster vaccination, VN antibodies increased in a different pattern for each serotype. Antibodies remained high for 12 months and increased strongly after the annual booster in 78% of the horses. PCR and virus isolation results remained negative. These results indicated that horses vaccinated with single serotypes need a booster after 6 months and simultaneously immunised horses after 12 months. No challenge infection could be carried out as facilities were not available. (Source: Equine Veterinary Education ) v African horse sickness vaccination RECENT CLINICALLY RELEVANT RESEARCH FROM AROUND THEWORLD In this study by Morgan Adkins and other researchers from the University of Georgia, the primary objective was to evaluate the association between serum metabolic parameters and the risk of bovine respiratory disease (BRD) in high-risk beef stocker calves (a stocker calf is 6 to 9 months of age and weighs 180 to 320 kg). Jugular venous blood samples were collected from mixed-breed beef bull, steer, and heifer calves (n=468) at the time of arrival processing at a stocker facility in northeast Georgia. Serum samples were then submitted for determination of serum creatinine, total calcium, phosphorus, magnesium, albumin, serum urea nitrogen, glucose, cholesterol, beta-hydroxybutyrate (BHBA), non-esterified fatty acid (NEFA), sodium, potassium, and chloride concentrations, as well as sodium:potassium ratio and NEFA:cholesterol ratio. Calves were monitored for the development of signs consistent with BRD for 45 days following arrival. A multi-variable logistic regression model was created to evaluate the association between serum variables and subsequent risk of BRD. In this analysis, BRD was associated with higher serum potassium, lower serum urea nitrogen, and lower BHBA concentrations at arrival processing. The area under the receiver operating characteristic curve for the ability of the model to predict morbidity was 0.645. These data suggest that hydration status, nutrient balance, and degree of rumen development may play a role in the development of BRD in high-risk beef stocker calves. (Source: The Bovine Practitioner ) v BOVINE Bovine respiratory disease Treatment of acute anaplasmosis in cattle In this study Douglas ShaneBayer and researchers from the USA the aim was to evaluate the effectiveness of enrofloxacin (ENR) 100mg/ml at a single subcutaneous dose of 12,5mg/kg of acute anaplasmosis (ANA) in mature beef cows (n=67). Following intravenous inoculation with A. marginale -infected blood, cattle were monitored for clinical signs of ANA. Upon meeting case criteria, cattle were randomly assigned to receive ENR or saline (SAL). Treatment success, defined as 28 d post-treatment survival and resolution of abnormal clinical scores, was 81.8% (27/33) and 44.1% (15/34) (P=0.0032) for ENR and SAL treated cows, respectively. Mortalitywas 47%(16/34) and3%(1/33) in SAL and ENR, respectively (P=0.0027). Packed cell volume at 7, 14, 21, and 28 d post-treatment was significantly greater in ENR compared to SAL (P<0.05). In this study, ENR improved treatment success compared to SAL, reduced ANA mortality, and maintained greater packed cell volumes post- clinical signs compared to SAL. (Source: The Bovine Practitioner ) v
Made with FlippingBook
RkJQdWJsaXNoZXIy OTc5MDU=